Related Experiment Videos
Study on COgnition and Prognosis in the Elderly (SCOPE)
Blood Pressure
|December 14, 1999
Summary
The SCOPE trial investigated candesartan cilexetil for mild hypertension in elderly patients. It assessed cardiovascular events, cognitive function, and mortality, providing key insights into hypertension management in seniors.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Background:
- Mild hypertension in the elderly is common, posing significant cardiovascular risks.
- Effective management strategies are crucial to improve prognosis and quality of life in this demographic.
Purpose of the Study:
- To evaluate the efficacy of candesartan cilexetil versus placebo in reducing major cardiovascular events in elderly patients with mild hypertension.
- To assess the impact of candesartan cilexetil on cognitive function, mortality, and health economics.
Main Methods:
- A multicentre, prospective, randomized, double-blind, parallel-group study (SCOPE) involving 4964 elderly patients (70-89 years).
- Patients received either candesartan cilexetil or placebo, with dosage adjustments based on blood pressure.
- Primary endpoint: major cardiovascular events. Secondary endpoints included cognitive function, mortality, and quality of life.
Main Results:
- Recruitment completed with 4964 randomized patients.
- Follow-up duration is 2 years, potentially longer if event rates are low.
- The study aims to provide comprehensive data on the benefits and risks of candesartan cilexetil in this population.
Conclusions:
- The SCOPE study provides valuable data on the cardiovascular and cognitive effects of candesartan cilexetil in elderly hypertensive patients.
- Findings will inform clinical practice regarding hypertension management in older adults.
- Further analysis will elucidate the drug's impact on mortality, renal function, and health economics.